Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells (Tregs) for the treatment of neurodegenerative, autoimmune, and metabolic diseases. The company focuses on three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Its lead asset, COYA 302, is a combination biologic consisting of low-dose interleukin-2 (COYA 301) and CTLA4-Ig, currently in a Phase 2 trial for amyotrophic lateral sclerosis (ALS). Coya also maintains an autologous Treg cell therapy program that has completed Phase 1 and Phase 2a studies in ALS. The company collaborates with Dr. Reddy's Laboratories on the development of COYA 302 for ALS. Coya’s operations are centered on research and development, clinical trials, and scaling manufacturing capacity to support potential commercialization.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage coyatherapeutics.com
Sector Healthcare IR page ir.coyatherapeutics.com/overview/default.aspx
Tags
regulatory t cells, neurodegenerative diseases, autoimmune diseases, metabolic diseases, cell therapy, biologics, exosomes, interleukin-2, ctla4-ig, als, COYA 302, COYA 301, LD IL-2, ALSTARS Trial, Dr. Reddy's Laboratories
Press page —

Metrics

Valuation  
Market cap $ 117.524M
Market cap (USD) $ 117.524M
P/E -3.60
PEG —
P/BV 3.50
P/S 25.06
P/OCF -5.38
P/FCF -10.94
Dividend yield —
Turnover / mcap —
Returns  
ROE -51.4%
ROI -49.3%
ROIC -39.3%
Profit margin -267.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 45
Quality score -73.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 7.946M 3.554M 6.002M — 0
Net profit -21.226M -14.881M -7.988M -12.245M -4.892M
Free cash flow -10.739M -10.289M -11.189M -7.239M -4.04M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 5.8 5.73 7.41 4.74 —
Price performance 12m 0.01 -0.23 0.56 — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 4.34M 5.93M 32.6M 38.3M 46.8M
Cash flow detail
Operating cash flow (USD) -3.9M -7.24M -11.2M -10.3M -10.7M
Change in payables (cash effect) (USD) 665,166 845,284 298,816 477,450 -527,006
Income taxes paid (cash effect) (USD) — — — -700,000 730,581
Share-based compensation (USD) 233,222 207,346 872,248 2.66M 4.29M
Income detail
Research and development expense (USD) 2.54M 4.41M 5.5M 11.9M 16.7M
Reported Mar 29, 2023 Mar 29, 2023 Mar 19, 2024 Mar 18, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.

“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics. “With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”

Recent Corporate Highlights

•Completed enrollment of 120 planned participants in the Phase 2/3 ALSTARS trial of COYA 302 for the treatment of ALS. Coya allowed participants in screening to enter the trial. A total of 137 participants were enrolled.

Oct 28, 2026

ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individuals

The Company believes implementation of a prospective stratification in the ALSTARS Trial based on baseline axonal injury burden, as measured by serum neurofilament light chain (NfL) levels, balances prognostic risk across arms, reduces baseline heterogeneity, and may improve the signal-to-noise ratio for the ALSFRS-R, the primary outcome measure

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. NEALS (Network of Excellence for ALS) is the world’s largest ALS research consortium, dedicated to accelerating the development of new treatments for ALS and Motor Neuron Disease (MND).

Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov ID: NCT07161999 ).

The poster describes a stratification methodology based on baseline NfL serum levels designed to mitigate the impact of ALS disease progression heterogeneity in interventional clinical trials. NfL is a structural protein component of the cytoskeleton found in neurons, particularly the axon, which is released into extracellular fluids (cerebrospinal fluid and blood) when neurons are damaged. Higher NfL levels are associated with faster clinical decline, as measured by the Revised ALS Functional Rating Scale (ALSFRS-R), and shorter survival. The baseline NfL levels from eligible individuals participating in the ALSTARS Trial were grouped into three tiers - low, medium and high - allowing for a prospective stratification and balanced randomization across treatment arms. Coya believes this stratification strategy strengthens the evaluation of the COYA 302 treatment effect, independent of chance cohort imbalances.

Details of the poster presentation:

Title: Mitigating Clinical Heterogeneity in ALS Trials: The Biological Rationale and Statistical Impact of 3-Tiered Neurofilament Light (NfL) Stratification in the ALSTARS Trial

Presenter/Authors: Tyrell J. Simkins, DO, PhD*, Fred Grossman, DO, Karen King, MS, Stanley Appel, MD, and James D. Berry, MD, MPH (*Presenting author)

Poster Session 1: October 28th, 2026, 4:30-6:30 PM ET

Poster Location: Opal Sands, Ballroom

Poster Number: 7

Following the presentation, a copy of the poster will be available here .

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive neurodegenerative disease that attacks motor neurons in the brain and spinal cord that control voluntary muscles, including those needed to speak, swallow and breathe. The disease progresses rapidly, with patients experiencing an average decline of approximately one point per month on the ALS Functional Rating Scale-Revised (ALSFRS-R), and 20% to 30% of patients dying within two years of diagnosis despite available therapies. Approximately 90% of ALS cases are sporadic, occurring in people with no family history of the disease. Current approved therapies provide only a modest treatment effect and slow, but do not stop, disease progression and functional decline, underscoring the significant unmet need for new treatment options that can meaningfully alter the course of the disease.

About the ALSTARS Trial

The ALSTARS Trial is a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of COYA 302 in patients with ALS. Approximately 120 subjects were randomized 1:1:1 to receive one of two pre-specified dosing regimens of COYA 302 or placebo during a 24-week double-blind treatment phase. Patients who complete the 24-week placebo-controlled phase enter a 24-week blinded active-treatment extension phase; patients receiving COYA 302 continue their assigned regimen, while placebo patients are re-randomized to one of the two COYA 302 dosing regimens, providing up to 48 weeks of data on COYA 302.

The primary endpoint is change in disease severity over time, as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score from baseline to Week 24 compared with placebo. Study objectives include evaluation of efficacy, safety and tolerability, biological activity, and biomarker levels.

Participants who complete the 48-week treatment period will be eligible to enroll in an open-label extension (OLE) to continue receiving COYA 302.

To learn more about the study, please visit ALSTARS Trial .

About COYA 302

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS and other neurodegenerative diseases. These mechanisms may have additive or synergistic effects.

Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (Identifier: NCT07161999).

COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Coya Therapeutics, Inc. — Other Events Bull 2 Bear 3 Clinical/regulatory

On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (“ALS”). The Company plans to initiate the OLE in response to requests from ALSTARS investigators and study participants. The OLE will provide participants who complete the 48-week treatment period with the opportunity to continue receiving COYA 302, while enabling the collection of longer-term efficacy and safety data. The Company expects the OLE to begin in November 2026 as the first cohort completes the 48-week treatment period. Concurrent with the anticipated initiation of the OLE, the Company expects to prioritize resources toward the ongoing clinical development of COYA 302 in ALS and assuring timely completion of important near-term milestones in the ALSTARS Trial. With this prioritization, the planned initiation of the Phase 2 clinical trial evaluating COYA 302 in frontotemporal dementia (“FTD”), previously anticipated in the second half of 2026, is now expected in 2027.

Prompts

Coya Therapeutics, Inc. (ticker COYA), listed in United States.

ETFs Holding Coya Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 92,062 $ 301.043K Nov 12, 2026
DXUV 0.00% 8,299 $ 27.138K Nov 12, 2026
DCOR 0.00% 4,560 $ 14.911K Nov 12, 2026
DFAC 0.00% 5,471 $ 17.89K Nov 12, 2026
DFSU 0.00% 137 $ 447.99 Nov 12, 2026
AVSC 0.00% 11,218 $ 33.654K Nov 16, 2026